Established tirzepatide for T2D. Notable for head-to-head superiority over insulin degludec.
Core trials
- SURPASS-1: tirz vs placebo
- SURPASS-2: vs sema 1.0 mg, superior A1c and weight
- SURPASS-3: vs titrated insulin degludec, superior A1c and weight, lower hypoglycemia
- SURPASS-4: vs glargine in T2D + CV risk
- SURPASS-5: tirz added to insulin glargine
- SURPASS-CVOT: CV outcomes, reads out 2026
FDA approval
Mounjaro approved 2022 for T2D.
Implications
Tirzepatide superior to titrated basal insulin in T2D — meaningful change to treatment intensification choices. CV outcomes expected 2026.